Home Japanese
Omega Investment Co., Ltd.

Chiome Bioscience

Chiome Bioscience (4583)

Securities Code
TYO:4583
Market Capitalization
7,719 million yen
IR Contact
ir@chiome.co.jp

Scoreboard

Discovery Development Capital Impact Overall Quartile
2.8 2.4 1.5 1.6 2.1 2

 

Company profile

An innovative biotech company with core competence in antibody generation. Focus on the development of robust and more effective therapeutics and diagnostics leveraging our novel antibody generation platforms.

 

Core technology

ADLib® system

ADLib® system represents “One-stop-order platform for antibody drug discovery”

 
The ADLib® system offers a platform library with unique array space that adds seamless Affinity maturation function. It is a one stop order drug discovery and research tool that can complete all the steps necessary for antibody drug discovery such as selection, full-length IgG expression, humanization, and affinity maturation on 1 platform.

Antibody selection with ADLib® – “Robust and simple method”

 
 
TribodyTM :Multi-specific antibody format

Tribody™ enables creation of unique antibody that differentiates from conventional antibody, by building multi-binding sites that bind to different antigen or epitope. This unique technology overcomes the key shortcomings of conventional mono- as well as of currently developed bi-specific antibody formats.

 

Active pipeline

CBA-1205, a therapeutic antibody for cancer that is currently in Phase I clinical trials, is a first-in-class antibody that targets DLK-1, while CBA-1535, a multivalent antibody that simultaneously targets tumour antigens and T cells, is the world’s first multivalent antibody in the Tribody format to undergo clinical trials. We expect to generate significant revenue from 2024 onwards by out-licensing both pipelines to pharmaceutical companies. In addition, we will create the third clinical development product following these by 2023.

Out-LicensedProduct

 

Top executive speaks to investors

 

News release

All


2022.11.14 Supplementary Information for Financial Results Q3 FY12/22
2022.11.14 Non-Consolidated Financial Results (Japanese GAAP) for the Nine Months Ended September 30, 2022
2022.10.11 Release of Research Publication of Affinity Maturation in ADLib® from Chiome Bioscience
2022.09.08 Publication of the Results from the Joint Research with CEINGE in generating new Tribodies aiming for Cancer Immunotherapy
2022.09.05 Presentation of preclinical data on PCDC, an anti-CDCP1 antibody drug conjugate, at World ADC San Diego 2022
2022.08.10 Supplementary Information for Financial Results Q2 FY12/22
2022.08.10 Non-Consolidated Financial Results (Japanese GAAP) for the Six Months Ended June 30, 2022
2022.07.13 Announcement of target-specific research and option agreement with Heidelberg Pharma
2022.07.11 Service agreement with option contract with Rohto Pharmaceutical Co., Ltd.
2022.07.04 First patient in of cancer therapeutic antibody CBA-1535 in a Phase 1 clinical trial
2022.06.13 Conclusion of contract with additional institutes and first dosing of CBA-1205 in the second part of Phase 1 study
2022.05.26 Announcement of collaborative research agreement with Kidswell Bio Corporation
2022.05.13 Supplementary Information for Financial Results Q1 FY12/22
2022.05.13 Non-Consolidated Financial Results (Japanese GAAP) for the Three Months Ended March 31,2022
2022.04.21 Announcement of Launch of a Diagnostic Kit by Fujirebio Inc.
2022.03.24 Release of Research Publication using Tribody™ Technology onto Cancer Immunotherapy from Chiome Bioscience in collaboration with Ceinge
2022.02.16 Submission of the application for a Phase I study of CBA-1535
2022.02.15 License agreement for a diagnostic kit with Fujirebio, Inc.
2022.02.14 Supplementary Information for Financial Results FY12/21
2022.02.14 Non-Consolidated Financial Results (Japanese GAAP) for the Fiscal Year Ended December 31, 2021
2021.12.24 Move to the second half part of Phase 1 clinical trial of first-in-class CBA-1205
2021.11.12 Supplement Documents for Financial Results Q3 FY12/21
2021.11.12 Non-Consolidated Financial Results (Japanese GAAP) for the Nine Months Ended September 30, 2021
2021.11.01 Extension of the Master Services Agreement with Chugai Pharmabody Research Pte., Ltd.
2021.10.18 Extension of the Master Services Agreement with Chugai Pharmaceutical Co., Ltd.
2021.10.12 Research Publication using Antibody generated by the ADLibⓇ System by Tokyo Medical and Dental University
2021.08.13 Supplement Documents for Financial Results Q2 FY12/21
2021.08.13 Non-Consolidated Financial Results (Japanese GAAP) for the Six Months Ended June 30, 2021
2021.07.27 Chiome Bioscience’s monoclonal antibody generation platform ADLib® technology has been introduced in a special edition of “Biopharma Dealmakers”, a Nature journal, featuring “Antibody Technologies” on the website.
2021.07.19 Company report about Chiome Bioscience Inc. has been issued by Omega Investment Co.,Ltd.
2021.05.14 Supplement Documents for Financial Results Q1 FY12/21
2021.05.14 Non-Consolidated Financial Results (Japanese GAAP) for the Three Months Ended March 31,2021
2021.05.14 Collaborative Research Agreement with Mologic Ltd. for antibody discovery and development
2021.05.14 Termination of Collaborative Development License and Exclusive Option Agreement for anti-Semaphorin 3A antibody
2021.02.09 Supplement Documents for Financial Results FY12/20
2021.02.09 Non-Consolidated Financial Results (Japanese GAAP) for the Fiscal Year Ended December 31, 2020
2021.01.14 License Agreement for anti-TROP-2 antibody development and commercialization

Pipeline


2022.10.11 Release of Research Publication of Affinity Maturation in ADLib® from Chiome Bioscience
2022.09.08 Publication of the Results from the Joint Research with CEINGE in generating new Tribodies aiming for Cancer Immunotherapy
2022.09.05 Presentation of preclinical data on PCDC, an anti-CDCP1 antibody drug conjugate, at World ADC San Diego 2022
2022.07.13 Announcement of target-specific research and option agreement with Heidelberg Pharma
2022.07.11 Service agreement with option contract with Rohto Pharmaceutical Co., Ltd.
2022.07.04 First patient in of cancer therapeutic antibody CBA-1535 in a Phase 1 clinical trial
2022.06.13 Conclusion of contract with additional institutes and first dosing of CBA-1205 in the second part of Phase 1 study
2022.05.26 Announcement of collaborative research agreement with Kidswell Bio Corporation
2022.04.21 Announcement of Launch of a Diagnostic Kit by Fujirebio Inc.
2022.03.24 Release of Research Publication using Tribody™ Technology onto Cancer Immunotherapy from Chiome Bioscience in collaboration with Ceinge
2022.02.16 Submission of the application for a Phase I study of CBA-1535
2022.02.15 License agreement for a diagnostic kit with Fujirebio, Inc.
2021.12.24 Move to the second half part of Phase 1 clinical trial of first-in-class CBA-1205
2021.11.01 Extension of the Master Services Agreement with Chugai Pharmabody Research Pte., Ltd.
2021.10.18 Extension of the Master Services Agreement with Chugai Pharmaceutical Co., Ltd.
2021.10.12 Research Publication using Antibody generated by the ADLibⓇ System by Tokyo Medical and Dental University
2021.05.14 Collaborative Research Agreement with Mologic Ltd. for antibody discovery and development
2021.05.14 Termination of Collaborative Development License and Exclusive Option Agreement for anti-Semaphorin 3A antibody
2021.01.14 License Agreement for anti-TROP-2 antibody development and commercialization

Finance

IR


2022.11.14 Supplementary Information for Financial Results Q3 FY12/22
2022.11.14 Non-Consolidated Financial Results (Japanese GAAP) for the Nine Months Ended September 30, 2022
2022.08.10 Supplementary Information for Financial Results Q2 FY12/22
2022.08.10 Non-Consolidated Financial Results (Japanese GAAP) for the Six Months Ended June 30, 2022
2022.05.13 Supplementary Information for Financial Results Q1 FY12/22
2022.05.13 Non-Consolidated Financial Results (Japanese GAAP) for the Three Months Ended March 31,2022
2022.02.14 Supplementary Information for Financial Results FY12/21
2022.02.14 Non-Consolidated Financial Results (Japanese GAAP) for the Fiscal Year Ended December 31, 2021
2021.11.12 Supplement Documents for Financial Results Q3 FY12/21
2021.11.12 Non-Consolidated Financial Results (Japanese GAAP) for the Nine Months Ended September 30, 2021
2021.08.13 Supplement Documents for Financial Results Q2 FY12/21
2021.08.13 Non-Consolidated Financial Results (Japanese GAAP) for the Six Months Ended June 30, 2021
2021.07.27 Chiome Bioscience’s monoclonal antibody generation platform ADLib® technology has been introduced in a special edition of “Biopharma Dealmakers”, a Nature journal, featuring “Antibody Technologies” on the website.
2021.07.19 Company report about Chiome Bioscience Inc. has been issued by Omega Investment Co.,Ltd.
2021.05.14 Supplement Documents for Financial Results Q1 FY12/21
2021.05.14 Non-Consolidated Financial Results (Japanese GAAP) for the Three Months Ended March 31,2021
2021.02.09 Supplement Documents for Financial Results FY12/20
2021.02.09 Non-Consolidated Financial Results (Japanese GAAP) for the Fiscal Year Ended December 31, 2020